DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Graham, Barney S ^a   Enama, Mary E ^a   Nason, Martha C ^a   Gordon, Ingelise J ^a   Peel, Sheila A ^b   Ledgerwood, Julie E ^a   Plummer, Sarah A ^a   Mascola, John R ^a   Bailer, Robert T ^a   Roederer, Mario ^a   Koup, Richard A ^a   Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON;

ADENOVIRUS 5; ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS PRESENTATION; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; FLUORESCENCE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOGENICITY; NEEDLE FREE INJECTION DEVICE; NORMAL HUMAN; PARTICLE SIZE; SYRINGE NEEDLE; TREATMENT RESPONSE; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DNA, RECOMBINANT; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; INJECTIONS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SAFETY; VACCINATION; VACCINES, DNA; YOUNG ADULT;

EID: 84876002357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059340     Document Type: Article

References (34)

1. Ledgerwood JE, Graham BS, (2009) DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases. Hum Vaccin 5: 623-626.
2. Tavel JA, Martin JE, Kelly GG, Enama ME, Shen JM, et al. (2007) Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 44: 601-605.
3. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194: 1650-1660.
4. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, et al. (2007) Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25: 4085-4092.
5. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, et al. (2006) A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13: 1267-1277.
6. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, et al. (2007) A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 196: 1732-1740.
7. Martin JE, Louder MK, Holman LA, Gordon IJ, Enama ME, et al. (2008) A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26: 6338-6343.
8. Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, et al. (2011) A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 203: 1396-1404.
9. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, et al. (2011) DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 11: 916-924.
10. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, et al. (2005) A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 79: 8828-8834.
11. Aguiar JC, Hedstrom RC, Rogers WO, Charoenvit Y, Sacci JB Jr, et al. (2001) Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 20: 275-280.
12. Jackson LA, Austin G, Chen RT, Stout R, DeStefano F, et al. (2001) Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19: 4703-4709.
13. Williams J, Fox-Leyva L, Christensen C, Fisher D, Schlicting E, et al. (2000) Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 18: 1939-1943.
14. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, et al. (2010) Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses. PLoS One 5: e9015.
15. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, et al. (2010) A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 201: 600-607.
16. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, et al. (2010) Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 5: e12873.
17. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, et al. (2011) A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). PLoS One 6: e21225.
18. De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, et al. (2011) HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol 187: 3391-3401.
19. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194: 1638-1649.
20. Peiperl L, Morgan C, Moodie Z, Li H, Russell N, et al. (2010) Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). PLoS ONE 5: e13579.
21. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, et al. (2007) Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13: 1032-1034.
22. Shu Y, Winfrey S, Yang ZY, Xu L, Rao SS, et al. (2007) Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25: 1398-1408.
23. Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR, (2010) Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA 304: 275-283.
24. Khurana S, Needham J, Park S, Mathieson B, Busch MP, et al. (2006) Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. J Acquir Immune Defic Syndr 43: 304-312.
25. Moodie Z, Huang Y, Gu L, Hural J, Self SG, (2006) Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods 315: 121-132.
26. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M, (1999) Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 77: 789-800.
27. Levine MM, (2003) Can needle-free administration of vaccines become the norm in global immunization? Nat Med 9: 99-103.
28. Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, et al. (2000) Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 43: 273-281.
29. Mathei C, Van Damme P, Meheus A, (1997) Hepatitis B vaccine administration: comparison between jet-gun and syringe and needle. Vaccine 15: 402-404.
30. Epstein JE, Gorak EJ, Charoenvit Y, Wang R, Freydberg N, et al. (2002) Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 13: 1551-1560.
31. Fisch A, Cadilhac P, Vidor E, Prazuck T, Dublanchet A, et al. (1996) Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route. Vaccine 14: 1132-1136.
32. Mumper RJ, Cui Z, (2003) Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Methods 31: 255-262.
33. Sardesai NY, Weiner DB, (2011) Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 23: 421-429.
34. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, et al. (2011) In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 6: e19252.